Envoy Medical, Inc. has reported its financial results for the third quarter of 2026, marking a significant step in the company’s ongoing efforts to advance its innovative hearing solutions. The report, filed on November 5, 2026, highlights the company's progress in its pivotal trial for a fully implanted cochlear implant, a product that aims to transform the hearing health landscape.

Brent Lucas, the Chief Executive Officer of Envoy Medical, expressed optimism about the company's trajectory, stating, “We continued to make significant progress with our investigational fully implanted cochlear implant during the third quarter, as we approach an extremely exciting 2027.” The trial has yielded encouraging data, with participants showing substantial improvements in speech perception.

Envoy Medical, which trades on the Nasdaq under the ticker symbols COCH and COCHW, operates in the orthopedic, prosthetic, and surgical appliances and supplies industry. The company has been making strides in its clinical trials and is working towards regulatory approvals for its innovative products. The recent filing, accession number 0001213900-26-116112, outlines the company's financial condition and operational results for the quarter.

Background

Founded in Delaware and based in White Bear Lake, Minnesota, Envoy Medical specializes in hearing health and neuroprosthetics. The company is recognized for pioneering fully implanted hearing solutions, particularly its Acclaim® cochlear implant. The firm is classified under the SIC code 3842, which pertains to orthopedic, prosthetic, and surgical appliances and supplies. Envoy Medical has been publicly traded since its merger with Anzu Special Acquisition Corp I in January 2021.

What the Filing Says

The filing indicates that Envoy Medical released a press statement regarding its financial results for the fiscal quarter ending September 30, 2026. The report emphasizes the company’s achievements in its clinical trials, including positive data from the first ten participants in their pivotal trial of the fully implanted cochlear implant. The mean Consonant-Nucleus-Consonant (CNC) word recognition score improved significantly, showcasing a 38 percentage point increase from the pre-implantation baseline.

Impact

This update is likely to impact various stakeholders, including investors, healthcare providers, and competitors within the orthopedic and surgical appliance industry. The promising results from the clinical trial may enhance Envoy Medical's market position and influence future investment decisions. The expansion of its intellectual property portfolio, with new patents granted in Canada and Hong Kong, further solidifies its competitive edge.

What's Next

Following the third quarter results, Envoy Medical is set to continue its regulatory efforts, having submitted the second module of its Modular Premarket Approval application to the FDA. The company expects to complete data collection for all participants by early in the second quarter of 2027, with the final module submission planned shortly thereafter. This proactive approach indicates a commitment to bringing innovative solutions to market, which could reshape the hearing health sector.